IndustryCompany release
Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M
Zentek Ltd. (ZTEKF) · Tue 17 Nov 2026
The Canadian company's interim results show earnings driven by a C$19.7M non-operating reversal, while sales stayed negligible and operating costs increased.
Zentek Ltd. has published unaudited interim financial statements for the quarter and six months ended 30 September 2026, approved by its board on 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Zentek Ltd. ↗
Article written by VigiEye from the official source (Zentek Ltd.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026